^
Association details:
| Biomarker: | No biomarker |
|---|---|
| Cancer: | Acute Myelogenous Leukemia |
| Drug: | cytarabine (DNA synthesis inhibitor, DNA-directed DNAP inhibitor) + idarubicin hydrochloride (Topoisomerase II inhibitor, DNA cross linking agent) + cladribine (Purinergic receptor P1 agonist) + Nugraf (filgrastim biosimilar) (G-CSF stimulant) |
| Direction: | Sensitive |
Evidence:
Source:
Excerpt:
Acute Myeloid Leukemia (Age >/=18 years)...THERAPY FOR RELAPSED/REFRACTORY DISEASE...Aggressive therapy for appropriate patients...Cladribine + Cytarabine + G-CSF +/- mitoxantrone or idarubicin
